The research highlights the growing interest in buccal drug administration, emphasizing its potential for rapid onset of action and enhanced patient compliance.Focusing on formulating oral disintegration strips (ODS) of Levetiracetam, an anticonvulsant crucial for epilepsy treatment, the study employs Hydroxy Propyl Methyl Cellulose E15 (HPMC-E15) as the polymer and Propyl Ethylene glycol-400 (PEG-400) as the plasticizer.The primary objective is to create a convenient and effective dosage form, addressing challenges associated with swallowing tablets or capsules, particularly in pediatric, geriatric, and dysphagic populations. ODS were prepared using the solvent casting method, with varying concentrations of HPMC-15 and PEG-400.Evaluation parameters included morphological properties, strip thickness, surface pH, content uniformity, disintegration time, and dissolution studies.The findings, particularly with the optimized formulation (X5), reveal positive attributes such as transparency, tensile strength, and folding endurance. Dissolution time ranged from 3 to 4 minutes, meeting acceptable moisture content limits. The study suggests that Levetiracetam ODS hold promise for epilepsy treatment, offering a swift onset of action and potentially improving patient compliance.The conclusion underscores that the optimized X5 formulation meets desired criteria for thickness, tensile strength, folding endurance, and dissolution time, making it a promising dosage form. The ODS technology extends beyond epilepsy, presenting opportunities for commercialization in Cosmeceuticals, Nutraceuticals, and various pharmaceutical applications. The study advocates for further research and commercialization efforts to ascertain broader acceptance and potential across diverse therapeutic areas.